SecBot SecBot
SECBOTREPLAY Home › Report › BWAY

BWAY · BrainsWay released new clinical data demonstrating that its FDA-cleared…

BrainsWay · PRESS-RELEASE filed Mar 4, 2026 at 07:30 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed Mar 4, 2026 at 07:30 ET

BrainsWay released new clinical data demonstrating that its FDA-cleared SWIFT™ accelerated Deep TMS protocol for major depressive disorder achieves comparable remission and response rates to the standard protocol in significantly fewer treatment days, reducing the acute phase from 20 visits to just 6 half-days. The data show an 87.8% response rate and 78.0% remission rate, with median time to remission cut from 28 to 21 days, supporting improved patient access and retention.

  • SWIFT™ protocol reduces acute treatment phase from 20 visits over 4 weeks to 6 half-days, a ~70% reduction in clinic visits
  • 87.8% response rate and 78.0% remission rate achieved with SWIFT, comparable to standard protocol
  • Median time to remission decreased to 21 days vs. 28 days with standard treatment
  • 70% of patients no longer had severe quality-of-life impairment; ~60% returned to normal-range functioning

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access